♦ The funding of rituximab (Rituxan) for the treatment of rheumatoid arthritis was initially reviewed in February 2007. At that time, the Committee
out, with only 5 patients having a baseline visit and no subsequent measures. Table 1 summarizes the baseline demographic features of the 2 treatment groups.
Table 2. Deﬁnitions of key terms and key assumptions for clinical scenarios for the 2012 ACR recommendations update for the treatment of RA* Deﬁnitions
Page 1 of 3 4141.1203 When to use this form This form must be completed by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid ...
Guidelines for the use and administration of Rituximab in Rheumatoid Arthritis Version 14 Minor update edits 22.7.09 Susan Oliver 1 of 13 ADMINISTRATION
Important information This form must be completed by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis.
Rheumatoid Arthritis (RA) B cell T cell Antigen-presenting cells B cell or macrophage Synoviocytes Pannus Articular cartilage Chondrocytes Macrophage HLA -DR
Guidelines doi:10.1093/rheumatology/ker106b BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis Marwan Bukhari1, Rikki Abernethy2, Chris Deighton3 ...
S14 Supplement to Journal of Managed Care Pharmacy JMCP November/December 2011 Vol. 17, No. 9-b www.amcp.org Biologic Agents in Rheumatoid Arthritis:
Rheumatoid Arthritis Ajay Bhatia Rheumatology Consultant. Hillingdon Hospital. email@example.com